FIELD: biotechnology.
SUBSTANCE: option of Fc-region of human IgG is proposed, FcγRIIb-binding activity which is maintained, and binding activities of this option with activating FcγR (FcγRIa, FcγRIIaR, FcγRIIaH and FcγRIIIaV) are reduced in comparison with the activity of Fc-region of native IgG. An antibody including the specified option of Fc region, a method for producing and application of this antibody to stimulate the removal of an antigen from plasma are also proposed.
EFFECT: invention makes it possible to reduce side effects, when using the antibody, induced by activating FcγR, while maintaining the capability of the antibody to eliminate antigens and while maintaining the capability to bind to FcγRIIb.
15 cl, 19 dwg, 23 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FcγRIIB | 2013 |
|
RU2812226C1 |
| ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FCΓRIIB | 2013 |
|
RU2736349C2 |
| VERSIONS OF FCΓRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2729831C2 |
| METHOD OF PRODUCING VARIANTS OF FCYRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2820161C1 |
| CARRIER CONTAINING A DRUG INTO A CELL FOR FORMING AN IMMUNE COMPLEX | 2012 |
|
RU2739792C1 |
| ANTIGEN-BINDING MOLECULE SPECIFIC TO TARGET TISSUE | 2013 |
|
RU2743463C2 |
| POLYPEPTIDE VARIANT THAT HAS PRESERVED OR DECREASED BINDING ACTIVITY TO FcγRIIa, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR APPLICATION | 2012 |
|
RU2749357C2 |
| ANTIGEN-BINDING MOLECULE INDUCING AN IMMUNE RESPONSE TO A TARGET ANTIGEN | 2012 |
|
RU2722829C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
| ANTIGEN-BINDING MOLECULE FOR ACCELERATING ANTIGEN LOSS | 2012 |
|
RU2772771C1 |
